Equities analysts expect Amarin Corporation PLC (NASDAQ:AMRN) to report $46.00 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Amarin Corporation PLC’s earnings, with the highest sales estimate coming in at $48.70 million and the lowest estimate coming in at $43.50 million. Amarin Corporation PLC posted sales of $32.73 million in the same quarter last year, which suggests a positive year-over-year growth rate of 40.5%. The business is scheduled to report its next quarterly earnings results before the market opens on Wednesday, November 1st.

According to Zacks, analysts expect that Amarin Corporation PLC will report full-year sales of $46.00 million for the current year, with estimates ranging from $166.80 million to $182.10 million. For the next year, analysts forecast that the business will post sales of $285.23 million per share, with estimates ranging from $223.30 million to $385.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Amarin Corporation PLC.

Amarin Corporation PLC (NASDAQ:AMRN) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.01. The company had revenue of $44.95 million during the quarter, compared to analyst estimates of $40.35 million. The business’s revenue for the quarter was up 37.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.07) earnings per share.

A number of equities analysts recently commented on the stock. BidaskClub cut shares of Amarin Corporation PLC from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. ValuEngine cut shares of Amarin Corporation PLC from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Jefferies Group LLC reiterated a “buy” rating and issued a $7.00 target price on shares of Amarin Corporation PLC in a research report on Thursday, August 3rd. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Amarin Corporation PLC in a research report on Thursday, August 3rd. Finally, Zacks Investment Research upgraded shares of Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research report on Monday, July 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $7.75.

Amarin Corporation PLC (AMRN) traded up 1.52% during mid-day trading on Friday, reaching $3.33. The company had a trading volume of 764,027 shares. Amarin Corporation PLC has a 12-month low of $2.75 and a 12-month high of $4.47. The firm’s market capitalization is $901.74 million. The firm has a 50-day moving average price of $3.35 and a 200 day moving average price of $3.34.

COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/10/28/amarin-corporation-plc-amrn-expected-to-announce-quarterly-sales-of-46-00-million.html.

In other Amarin Corporation PLC news, insider Steven B. Ketchum sold 63,479 shares of the business’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $3.48, for a total value of $220,906.92. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 3.72% of the stock is owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd increased its position in shares of Amarin Corporation PLC by 94.2% in the second quarter. Dynamic Technology Lab Private Ltd now owns 87,104 shares of the biopharmaceutical company’s stock valued at $351,000 after acquiring an additional 42,246 shares during the period. Westside Investment Management Inc. increased its position in shares of Amarin Corporation PLC by 1.1% in the second quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 300 shares during the period. State Street Corp increased its position in shares of Amarin Corporation PLC by 1.3% in the second quarter. State Street Corp now owns 201,995 shares of the biopharmaceutical company’s stock valued at $814,000 after acquiring an additional 2,640 shares during the period. Intrinsic Edge Capital Management LLC purchased a new position in shares of Amarin Corporation PLC in the second quarter valued at about $725,000. Finally, Stonepine Capital Management LLC purchased a new position in shares of Amarin Corporation PLC in the second quarter valued at about $302,000. Hedge funds and other institutional investors own 37.76% of the company’s stock.

Amarin Corporation PLC Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Get a free copy of the Zacks research report on Amarin Corporation PLC (AMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amarin Corporation PLC (NASDAQ:AMRN)

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.